NEW PORT RICHEY, Fla., Jan. 29, 2019 (SEND2PRESS NEWSWIRE) — The C. Diff Foundation Board of Directors announced today that the 2019 \u201cAbove and Beyond\u201d Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.<\/p>\n
![\"C](\"https:\/\/www.send2press.com\/wire\/images\/19-0129-cdiff-foundation-696x522.jpg\" "\\"C")
\n\u201cWe are very proud to recognize Ms. Jones with our \u201cAbove and Beyond\u201d award,\u201d said C. Diff Foundation Founder and President, Nancy Caralla. \u201cLee\u2019s dedication to the entire C. diff community of patients, family members, and physicians hasn\u2019t wavered since the founding of Rebiotix in 2011. She is a true example of what can happen when focusing on patient well-being drives new approaches to healthcare.\u201d<\/p>\n
The award will be presented by the Foundation\u2019s Vice President, Scott Battles, and Treasurer Angelo Ortiz at the Rebiotix facility.<\/p>\n
\u201cIt\u2019s an honor to receive this award from the C. Diff Foundation,\u201d said Ms. Jones. \u201cThe purpose of starting Rebiotix was to bring the power of the microbiome to the clinic in a scientifically sound, quality-controlled way to help patients. We stand with the Foundation in believing that patient well-being should be at the core of all that we do, from clinical trials to exploring new scientific landscapes within the microbiome space.\u201d<\/p>\n
About the C Diff Foundation:<\/strong> About Rebiotix Inc.:<\/strong> Rebiotix\u2019s clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering\u00a0Microbiota Restoration Therapy™ platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit\u00a0https:\/\/www.rebiotix.com\/<\/a><\/p>\n Twitter: @cdiffFoundation #CdiffInfection #Clostridiumdifficile @Rebiotix<\/p>\n","protected":false},"excerpt":{"rendered":" NEW PORT RICHEY, Fla., Jan. 29, 2019 (SEND2PRESS NEWSWIRE) — The C. Diff Foundation Board of Directors announced today that the 2019 “Above and Beyond” Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.<\/p>\n","protected":false},"author":66,"featured_media":44021,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[67,1,571,14,61,56],"tags":[326,10736],"class_list":["post-44056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-awards-and-honors-news","category-business-news","category-pharma-news","category-florida-news","category-health-medical-news","category-non-profit-news","tag-clostridium-difficile","tag-rebiotix","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":6311,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/44056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/66"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=44056"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/44056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media\/44021"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=44056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=44056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=44056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nThe\u00a0C Diff Foundation<\/a>\u00a0is a non-profit, 501(c)(3) organization established in 2012. It is comprised of 100% volunteering professionals dedicated to supporting public health through education and advocacy for\u00a0C.\u00a0difficile\u00a0infection prevention, treatments, environmental safety and support world-wide. The Foundation\u2019s CEO and founder is a nurse inspired to create the foundation after witnessing the loss of her father to CDI, as well as suffering from the infection herself. The C Diff Foundation members, with their volunteer patient advocates, successfully \u201craise C. diff awareness\u201d locally and in over fifty-six (56) countries and host a U.S. nation-wide hotline (1-844-FOR-CDIF) to support healthcare providers, patients and families through the difficulties of a C. diff infection. Learn more: https:\/\/cdifffoundation.org\/<\/a><\/p>\n
\nRebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and\u00a0diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent\u00a0Clostridium difficile\u00a0(C. diff) infection. RBX2660 has been granted\u00a0Fast Track, Orphan and\u00a0Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.<\/p>\n